Note 9 - License Agreements (Details Textual) - USD ($)			1 Months Ended	3 Months Ended			12 Months Ended
	Jan. 07, 2024	Jul. 28, 2023	Dec. 31, 2012	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2023	Jan. 31, 2012
Income Tax Expense (Benefit)				$ 29,000
Deferred Revenue, Current				3,373,000			$ 152,000
Precision BioSciences, Inc. [Member]
Investment Purchased Balance Shares (in shares)	2,920,816
Investment Purchased Balance Price Per Share (in dollars per share)	$ 0.77
L F B License Agreement [Member]
License And Collaboration Agreement, Expenses Incurred				31,000,000
Royalty Expense				4,900,000		$ 800,000
Accrued Royalties				4,900,000
L F B License Agreement [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)								15 years
Sublicense Agreement With Ildong Pharmaceutical Co [Member]
Upfront Fee Received From Sub License			$ 2,000,000
Income Tax Expense (Benefit)			300,000
License Revenue				38,000		$ 38,000
Deferred Revenue				300,000			500,000
Deferred Revenue, Current				200,000
Additional Amount Receivable on Achievement of Pre-specified Milestones			$ 5,000,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			15 years
Commercialization Agreement With Neuraxpharm [Member]
Additional Amount Receivable on Achievement of Pre-specified Milestones		$ 492,500,000
License and Collaboration Agreements, One-time, Non-refundable Payment		140,000,000			$ 140,000,000		$ 140,000,000
Additional Payments Upon Key Market Commercial Launch		$ 12,500,000
Royalty Percentage on Net Product Sales		30.00%
Agreement Buyback Period (Year)		2 years
Commercialization Agreement With Neuraxpharm [Member] | Royalty [Member] | Maximum [Member]
Revenues				$ 100,000
Precision License Agreement [Member]
License Agreement, Amount Paid Upfront	$ 7,500,000
License Agreement, Amount Paid Upfront, Cash	5,250,000
License Agreement, Amount Paid Upfront, Equity Investment	2,250,000
License Agreement, Deferred Payment	$ 2,500,000
License Agreement, Percentage of Premium on Equity Investment	100.00%
License Agreement, Share Price, Trading Days (Day)	30 days
License Agreement, Additional Milestone Payments	$ 293,000,000
Term After First Commercial Sale (Year)	10 years